ADMA vs CSL

For growth investors, ADMA Biologics, Inc.

(ADMA) is the stronger pick with 19. 6% revenue growth year-over-year, versus 0. 3% for Carlisle Companies Incorporated (CSL). ADMA Biologics, Inc. (ADMA) offers the better valuation at 14. 1x trailing P/E (9. 7x forward), making it the more compelling value choice. Analysts rate ADMA Biologics, Inc. (ADMA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ADMA Biologics, Inc.

(ADMA) is the cheapest at 14. 1x versus Carlisle Companies Incorporated at 21. 1x. On forward P/E, ADMA Biologics, Inc. is actually cheaper at 9. 7x.

Over the past 5 years, ADMA Biologics, Inc.

(ADMA) delivered a total return of +386. 8%, compared to +95. 1% for Carlisle Companies Incorporated (CSL). Over 10 years, the gap is even starker: CSL returned +277. 3% versus ADMA's +34. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Carlisle Companies Incorporated (CSL) is the lower-risk stock at 1.

18β versus ADMA Biologics, Inc. 's 1. 25β — meaning ADMA is approximately 6% more volatile than CSL relative to the S&P 500. On balance sheet safety, ADMA Biologics, Inc. (ADMA) carries a lower debt/equity ratio of 17% versus 160% for Carlisle Companies Incorporated — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ADMA Biologics, Inc.

(ADMA) is pulling ahead at 19. 6% versus 0. 3% for Carlisle Companies Incorporated (CSL). On earnings-per-share growth, the picture is similar: ADMA Biologics, Inc. grew EPS -25. 9% year-over-year, compared to -38. 6% for Carlisle Companies Incorporated. Over a 3-year CAGR, ADMA leads at 49. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ADMA Biologics, Inc.

(ADMA) is the more profitable company, earning 28. 8% net margin versus 14. 8% for Carlisle Companies Incorporated — meaning it keeps 28. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ADMA leads at 37. 5% versus 19. 9% for CSL. At the gross margin level — before operating expenses — ADMA leads at 57. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, ADMA Biologics, Inc.

(ADMA) trades at 9. 7x forward P/E versus 17. 2x for Carlisle Companies Incorporated — 7. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ADMA: 147. 9% to $21. 00.

In this comparison, CSL (1.

2% yield) pays a dividend. ADMA does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Carlisle Companies Incorporated (CSL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

18), 1. 2% yield, +277. 3% 10Y return). Both have compounded well over 10 years (CSL: +277. 3%, ADMA: +34. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ADMA (Healthcare) and CSL (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ADMA is a small-cap high-growth stock; CSL is a mid-cap quality compounder stock. CSL pays a dividend while ADMA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.